← All trials
NCT05816668
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 30, 2023
- Primary completion
- Apr 30, 2024
- Completion date
- Sep 30, 2024
- First posted
- Apr 18, 2023
- Last posted
- Apr 18, 2023
- Enrollment
- 122
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Instituto do Cancer do Estado de São PauloLead sponsor
- Instituto do Cancer do Estado de São PauloOverall official - principal investigator
- Instituto do Cancer do Estado de São PauloReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.